Real-World Multicenter Study of PD-1 Blockade in HIV-Associated Classical Hodgkin Lymphoma Across the United States

By sjmartinez • May 8, 2024

Lurain K, Zarif TE, Ramaswami R, Nassar AH, Adib E, Abdel-Wahab N, Chintapally N, Drolen CE, Feldman T, Haykal T, Nebhan CA, Kambhampati S, Li M, Mittra A, Lorentsen M, Kim C, Drakaki A, Morse M, Johnson DB, Mangla A, Dittus C, Ravi P, Baiocchi RA, Chiao EY, Rubinstein PG, Yellapragada SV, LaCasce AS, Sonpavde GP, Naqash AR, Herrera AF. Real-World Multicenter Study of PD-1 Blockade in HIV-Associated Classical Hodgkin Lymphoma Across the United States. Clin Lymphoma Myeloma Leuk. 2024 Apr 5:S2152-2650(24)00134-4. doi: 10.1016/j.clml.2024.03.011. Epub ahead of print. PMID: 38714474.

Tags: Anti-PD-1, checkpoint inhibitors, General Internal Medicine, Hematology/Oncology, HIV/AIDS, Publications, Resident

Investments in Childhood Community Resources and Subsequent Adult Health Outcomes

La Charite J, Dudovitz R, Choi K, Chen K, Jackson NJ, Nuckols T, Sastry N, Schickedanz A, Wong MD, Zimmerman FJ. Investments in Childhood Community[...]

Creation of a Multidisciplinary Cycling Medicine Clinic: Analysis of the First 9 Years

Searle O, Rice S, Fowler C, Kotler DH. Creation of a Multidisciplinary Cycling Medicine Clinic: Analysis of the First 9 Years. Curr Sports Med Rep.[...]

Glucagon-Like Peptide-1 Based Therapies and the Risk of Severe Gastrointestinal Motility Adverse Events: A Cohort Study

Alkabbani W, Crisafulli S, Paik JM, Tavakkoli A, Bykov K, Glynn RJ, Wexler DJ, Patorno E. Glucagon-Like Peptide-1 Based Therapies and the Risk of Severe[...]